Novartis spies new potential for Xolair with CSU filings
This article was originally published in Scrip
Novartis is hoping to carve out another niche for its anti-IGE monoclonal antibody product for moderate to severe asthma, Xolair (omalizumab), this time in chronic spontaneous urticaria (CSU, also known as chronic idiopathic urticaria).
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.